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Abstract: Post kala-azar dermal leishmaniasis (PKDL) is a skin complication resulting from 
infection with Leishmania donovani (LD) parasite. It mostly affects individuals who have previ-
ously suffered from visceral leishmaniasis (VL) caused by LD. In some cases, PKDL develops 
among people infected with LD, but do not show any symptoms of VL. Clinical presentation 
includes hypopigmented macules/papules/nodules or polymorphic lesions (combination of 
two or more lesions). Except for skin lesions, PKDL patients are generally healthy and usually 
do not seek medical care. These patients play an important role in interepidemic transmission 
of the infection and subsequent VL outbreak. Therefore, proper diagnosis and treatment of 
PKDL patients is important for the control of VL in endemic countries, especially in the Indian 
subcontinent where VL is anthroponotic. Here, we report the challenges in the estimation of 
PKDL burden, its diagnosis, and treatment, and suggest possible solutions based on recent 
literature, reports, published manuals, and web-based information.
Keywords: post kala-azar dermal leishmaniasis, Bangladesh, challenge, treatment, diagnosis, 
prevention
Challenges for post kala-azar dermal  
leishmaniasis case management
Differences in incidence and clinical presentation  
depending on geographical areas
Post kala-azar dermal leishmaniasis (PKDL) is a skin manifestation of infection caused 
by Leishmania donovani (LD) parasite.1 It develops mostly in patients who have been 
previously cured from visceral leishmaniasis (VL).1 Thus, it is considered as a com-
plication of VL. However, several studies demonstrated that PKDL developed among 
individuals who were infected with LD without developing VL.2,3 Fortunately, these 
are observed in only a small proportion of PKDL cases (6%–10%).2,3 Para-PKDL 
are cases in which patients have VL and PKDL at the same time.4 Para-PKDL is 
rare in the Indian subcontinent and is seen among 16% of PKDL cases in Sudan.5 
PKDL can also be caused by Leishmania infantum in HIV-infected patients.4 In the 
Indian subcontinent, PKDL was first described by Brahmchari in 1922 as “dermal 
leishmanoid” because LD bodies had been observed in lesion smears. Later, the condi-
tion was renamed as post kala-azar dermal leishmaniasis.6 In Sudan, Christopherson 
first described PKDL in 1921.7
Skin manifestations of PKDL include hypopigmented macular/papular/nodular 
or polymorphic lesions as well as a combination of these conditions. Involvement Research and Reports in Tropical Medicine 2014:5 submit your manuscript | www.dovepress.com
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of the mucosa and other associated symptoms such as 
itching are rare.1 Interestingly, the clinical manifestation 
of PKDL shows regional characteristics. Sudanese with 
PKDL presents mostly nodular lesions, whereas most of the 
PKDL cases in Bangladesh show hypopigmented macular 
lesions1–3,8 (Figures 1–3). Reasons behind this interesting 
phenomenon in the presentation of the disease are obscure. 
Apart from skin lesions, PKDL patients are clinically 
healthy and can perform daily activities.2,3,8 This explains 
why these patients usually do not seek medical care, and 
they remain unnoticed by the health system if they have not 
been actively researched. PKDL patients, especially those 
with papules and nodules, continue to transmit the infection 
to others through sandfly bites. Studies in the past have suc-
cessfully demonstrated that the parasites can be transmitted 
from papular and nodular lesions through sandfly bites.9 
However, it remains to be determined whether PKDL can 
also be transmitted from hypopigmented macular lesions. 
Theoretically, they should be because in 45% of clinically 
defined PKDL cases with hypopigmentation, their lesions 
were shown to have parasite DNA.1,8 Parasite DNA was 
also isolated from the peripheral blood of PKDL cases with 
macular lesions.8 Nevertheless, experimental xenodiagnosis 
is ultimately required to understand the potential of LD 
transmission through macular lesions of PKDL. Underly-
ing host and parasite factors that make PKDL capable of 
transmitting infection are very important from a public 
health perspective.
Current literature shows that PKDL is most com-
mon in Sudan and Bangladesh.10 PKDL also occurs 
among cured VL patients in India, Nepal, and Ethiopia. 
However, the incidence is less in these countries than in 
Sudan and   Bangladesh.10 PKDL incidence among sodium 
  stibogluconate (SSG)-treated VL patients is about 50% in 
Sudan within 6 months after treatment. In Bangladesh, the 
incidence of PKDL from VL after treatment with SSG is 
about 19% within 5 years after treatment.3 The median time 
for the incidence of PKDL in India is about 2 years from the 
time of treatment.2,8 It has been speculated that the devel-
opment of PKDL could be linked to treatment with SSG/ 
antimonials.12 Since antimonials have been the only drugs in 
use for the treatment of VL for almost 70 years, it is difficult 
Figure 1 Macular form of post kala-azar dermal leishmaniasis.
Figure 2 Papular post kala-azar dermal leishmaniasis.
Notes: Reproduced from The Post Kala-azar Dermal Leishmaniasis Atlas: A manual for 
health workers. Zijlstra ee, Alvar J. Geneva: world Health Organization. wHO/HTM/
NTD/iDM/2012.4. © 2012. Available from: http://apps.who.int/iris/bitstream/10665/
101164/1/9789241504102_eng.pdf. Accessed October 3, 2014.11
Figure 3 Nodular papular post kala-azar dermal leishmaniasis.
Notes: Reproduced from The Post Kala-azar Dermal Leishmaniasis Atlas: A manual for 
health workers. Zijlstra ee, Alvar J. Geneva: world Health Organization. wHO/HTM/
NTD/iDM/2012.4. © 2012. Available from: http://apps.who.int/iris/bitstream/10665/
101164/1/9789241504102_eng.pdf. Accessed October 3, 2014.11Research and Reports in Tropical Medicine 2014:5 submit your manuscript | www.dovepress.com
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to simply link antimonials with PKDL. Furthermore, recent 
reports demonstrated that PKDL developed after treatment 
of VL with other drugs.13,14 Current available options for 
treatment of VL are miltefosine, paromomycin, liposomal 
amphotericin B, and amphotericin B deoxycholate. These 
could be used alone or in combinations: amphotericin B 
deoxycholate with miltefosine/paromomycin, miltefosine 
with liposomal amphotericin B, or paromomycin with lipo-
somal amphotericin.15 If some of these treatment regimens 
are found to be protective against PKDL, it will be good 
news for public health policymakers. Therefore, either ret-
rospective or prospective studies to explore the incidence 
of PKDL in relation to the various treatment regimens are 
needed especially in the Indian subcontinent where VL is 
only anthroponotic.
During the period of 1960–1970, VL disappeared from 
Bangladesh as a result of DDT (dichlorodiphenyltrichlo-
roethane) sprays for malaria eradication.16 It subsequently 
re emerged in the early 1980s as reported in the literature, 
first for PKDL cases, followed by reports of VL outbreaks.17–20 
A recent report from Assam, India, showed that the outbreak 
of VL occurred in the same areas where VL had been a seri-
ous public health problem 70 years ago.21 Theoretically, the 
existence of a single case of PKDL can be a risk for new 
outbreak of VL. Thus, a complete survey of the absolute 
burden of PKDL in VL-affected countries is essential. 
Although there are some reports about the incidence of 
PKDL in the Indian subcontinent and in Africa, there is no 
survey for the estimation of PKDL burden with case map-
ping in VL endemic countries. The report from Assam further 
emphasizes the need for such a study as well as a thorough 
surveillance of VL-affected areas.21 It is evident that map-
ping of past and current VL as well as untreated PKDL cases 
is important for effective monitoring and to strengthen VL 
control strategies.
Diagnosis
The diagnosis of PKDL remains a big challenge for experts, 
especially in the macular form of the disease.10,22 LD para-
site can be demonstrated in 90% of skin specimens of cases 
with nodular lesions. Unfortunately, in macular cases, the 
sensitivity of conventional microscopic examination of skin 
specimens is only about 3%.8,22,23 Adams et al24 reviewed and 
assessed the sensitivity and specificity of existing diagnos-
tic tools for PKDL but failed to estimate the sensitivity of 
macular type PKDL. As such, the diagnosis of PKDL still 
relies on clinical criteria that include history of VL/exposure 
to VL endemic areas, skin lesions, and positivity for rK39 
strip test combined with the exclusion of diseases like leprosy 
and fungal skin infection.2,3,8,10,24 There is therefore an urgent 
need for new diagnostic tool(s) with high sensitivity and 
specificity for PKDL.
Treatment
The most important challenge for management of PKDL is 
the treatment of PKDL. Until now, SSG is the only option for 
the treatment of PKDL.25 Treatment includes intramuscular 
injection with SSG at a dose of 20 mg/kg/day for 20 consecu-
tive days per month for 6 months (120 injections in total). 
Injections with SSG are very painful and serious adverse 
events including death from sudden cardiac arrest have been 
observed.26,27 Thakur et al27 in their observational study with 
80 VL patients with SSG treatment observed different types 
(abnormal P, R, T waves; elevation/depression of ST segment; 
and prolonged QT interval) of cardiac toxicity in 6%–40% 
of cases and death due to cardiac toxicity among 5%. Other 
minor side effects included loss of appetite, metallic taste 
in mouth, and arthralgia. Other studies also reported SSG-
related cardiac toxicties.28,29 This is one of the reasons why 
PKDL patients usually do not seek medical care, and treat-
ment compliance is frequently low when they receive SSG 
treatment.8 Thus, a safe, effective, and affordable treatment 
regimen for PKDL with shorter duration is urgently needed. 
Otherwise, PKDL patients will be left untreated and this will 
jeopardize the efforts of the national VL elimination program 
in Bangladesh and in the Indian subcontinent.
Alternative drugs for PKDL are miltefosine, amphot-
ericin B, liposomal amphotericin B, and immunotherapy in 
combination with SSG. Thakur et al30 compared the efficacy 
of amphotericin B with SSG and found that amphotericin B 
was superior to SSG for the treatment of PKDL patients in 
India. However, the nephrotoxicity caused by amphoteri-
cin B coupled with high costs have limited its use.30 The 
results of the trial using liposomal amphotericin B for the 
treatment of PKDL by Médecins Sans Frontières, Holland 
program in Fulbaria, Bangladesh, showed that 90% had 
some response to treatment and 34% had complete resolu-
tion of skin lesions by 12 months after treatment.10 Another 
alternative for SSG therapy is the combination of SSG with 
immunotherapy. So far only one study reported a high cure 
rate (87%) of PKDL with immunotherapy in Sudan.31 The 
immunotherapy was based on the combination of SSG 
with the first-generation vaccine (alum-precipitated auto-
claved Leishmania major plus Bacillus Calmette -Guérin). 
However, the risk for serious adverse events from SSG and 
autoclaved L. major cannot be eliminated.Research and Reports in Tropical Medicine 2014:5 submit your manuscript | www.dovepress.com
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Future directions to improve  
PKDL case management
improve PKDL case detection
As mentioned earlier, PKDL patients especially in the Indian 
subcontinent are otherwise healthy except for skin lesions 
and they usually do not self-report to the hospital for medical 
care. Therefore, active detection of PKDL cases either by 
periodic camp approach or house to house visit of past VL 
cases is useful for the detection and treatment of PKDL cases. 
Huda et al32 in their multicenter study reported that PKDL 
case detection can be improved by 40% by implementing the 
camp approach. To reduce transmission of VL, the national 
VL elimination program in the Indian subcontinent is con-
ducting indoor residual spraying with insecticides in houses 
of VL endemic villages at least twice. Before spraying, the 
spray team is required to perform a household visit to instruct 
the household head and members to take some actions and 
precautions. The spray team leader is usually a healthcare 
worker from the hospital. This provides an excellent oppor-
tunity to implement active case detection for PKDL if the 
healthcare worker is trained in the detection method. Another 
option is heath education to VL patients during treatment for 
VL in the hospital. If a VL patient is educated about PKDL, 
especially its clinical symptoms and treatment options by 
his/her doctor or nurse, then it may improve self-reporting 
of PKDL patients to the hospital for treatment. Another 
opportunity is to ensure periodic follow-up of treated VL 
patients for PKDL by providing incentives against his/her 
daily wage loss and by providing transportation to the hospital 
using the health system or a public–private partnership. 
Implementation research regarding any of above-mentioned 
options may help to establish the most cost-effective method 
for improving PKDL case detection. Support from donor 
agencies will be needed since PKDL is highly neglected 
among neglected tropical diseases.
improve diagnosis
Comparatively few studies have been carried out to improve 
diagnosis of PKDL. The conventional method for diagnosis 
of PKDL using light microscopy and skin specimens is 
not satisfactory and is especially frustrating for macular 
PKDL.8,9,24 Serological tests aimed at detection of antibod-
ies against Leishmania in the blood do not help much since 
most PKDL patients have previously suffered from VL, and 
antibodies against Leishmania persist for years. However, 
it is useful for the diagnosis of PKDL patients who have 
not previously suffered from VL. Molecular tests such as 
detection of LD DNA by Leishmania-specific nested (Ln) 
polymerase chain reaction (PCR) in skin specimens are very 
sensitive for nodular and papular lesions and are satisfactory 
for the macular form of the disease.8,24 The problem with Ln-
PCR is that there is a high probability of contamination and 
it is time consuming. The study by Verma et al33 showed that 
quantitative PCR using skin specimens and Taqman probe 
is very promising for the diagnosis of PKDL. However, its 
high cost limits its implementation by public health systems. 
Research for the development of antigen-detection tests from 
skin specimens or in blood/urine and fluorescence-based 
diagnostic tools using skin specimens are highly desired to 
develop cost-effective methods for diagnosis of PKDL.
improve treatment
Safe and highly effective drugs are urgently needed for the 
treatment of PKDL cases especially in the Indian subcontinent. 
Among the new anti-leishmanial drugs (miltefosine, liposomal 
amphotericin B, paromomycin, and a combination of any two), 
only liposomal amphotericin B (AmBisome®) and miltefosine 
monotherapy have been tested for their efficacy in the treat-
ment of PKDL.10,34,35 Therapy with liposomal amphotericin B 
resulted in different results in Sudan and Bangladesh. In Sudan, 
Musa et al10,35 reported promising results with AmBisome 
monotherapy at a dose of 2.5 mg/kg/day for 20 days. It showed 
83% of cure rate in persistent PKDL patients who were 
resistant to SSG therapy. Another advantage of this treatment 
regimen is its comparatively shorter duration of treatment, 
which is 20 days, as well as its safety. However, the study 
enrolled only 12 PKDL patients, which is relatively small 
in size and necessitates further replication of this treatment 
regimen with a large number of patients to make a definite 
conclusion. Conversely, Médecins Sans Frontières, Holland 
program in Fulbaria, Bangladesh, found 34% complete cure 
within 12 months of treatment with liposomal amphotericin B 
using a different dose schedule.10
Miltefosine (hexadecylcholine, C12H46NO4P) is a phos-
pholipid derivative, structurally related to a phospholipid 
component of the cell membrane.36 Its anti-leishmanial action 
was discovered by Croft et al in 1987.36 Following this dis-
covery, miltefosine had been widely studied for its oral use 
as an anti-leishmanial drug at a dose of 2.0–2.5 mg/kg/day 
for 4 weeks. It was highly effective against Indian VL with 
a cure rate of 83%–94%.37,38 Based on these studies in 2007, 
miltefosine had been adapted for the treatment of VL for 
both adults and children (.2 years old) by the national VL 
elimination program in Bangladesh, India, and Nepal.
In 2004, Soto et al39 reported its efficacy for the treatment 
of cutaneous leishmaniasis caused by Leishmania (Viannia) Research and Reports in Tropical Medicine 2014:5 submit your manuscript | www.dovepress.com
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panamensis in Colombia. Miltefosine was also reported 
to be highly effective against cutaneous leishmaniasis by 
several other studies.40,41 However, in these studies, subjects 
were mostly adults and treatment with miltefosine was for 
1 month.
Following the reports of treatment of cutaneous leishma-
niasis with miltefosine, Belay et al42 and Rihl et al43 almost 
simultaneously reported one and two cases of PKDL HIV 
coinfection successfully treated with miltefosine in 2005. 
In the following year, Sundar et al reported the first case of 
PKDL unresponsive to SSG, but successfully treated with 
miltefosine.44 In subsequent years, several other studies have 
reported successful treatment of PKDL with miltefosine.45,46 
Among these reports, only the study reported by Modak et al 
in 2010 included two children out of a total of six patients, 
who were treated successfully with miltefosine for 8 weeks.34 
Ramesh et al47 found that adult PKDL patients could be 
treated with miltefosine daily for 8–12 weeks at a dose of 
50 mg, three times a day with a cure rate of 96%. Data from 
randomized control trials with miltefosine for PKDL were 
not available until January 2013 when Sundar et al showed 
that 12 weeks treatment with miltefosine for PKDL in adults 
was superior to 8 weeks treatment.48 The efficacy was 76% 
and 81% for 8 weeks and 12 weeks treatment regimens, 
respectively. So far, this is the only randomized clinical trial 
for the treatment of PKDL with miltefosine monotherapy 
for 12 weeks. However, the efficacy and safety of 12 weeks 
miltefosine treatment in children are unknown. A recent 
study in Bangladesh showed that children and adolescents 
are the most common victims of PKDL.3 Again further 
studies/trails are needed to confirm the efficacy and safety 
of miltefosine for PKDL in children. An open trial is under 
way in Bangladesh and its results will be available very soon 
(our study). We are also planning another study to investigate 
the safety and efficacy of 12 weeks miltefosine treatment in 
children and adolescents in Bangladesh.
Combination therapy is another attractive option for the 
treatment of PKDL. Ramesh et al49 reported two cases treated 
with amphotericin B and miltefosine. Combination therapy 
has the advantage of reducing the dose and duration to ensure 
better tolerance and compliance. The combination therapy 
of AmBisome plus miltefosine, AmBisome plus paromo-
mycin, and miltefosine plus paromomycin has already been 
shown to be very safe and effective for VL.50 The efficacy 
and duration of combination therapy against PKDL are yet 
to be established.
Fexinidazole is a new oral drug. It is a 2-substituted 
5-nitroimidazole formulation. Currently, its efficacy and 
safety for VL is under trial in Sudan.51 If it is successful, this 
drug could also be tested for its efficacy against PKDL.
Prevention of PKDL
Prevention is better than cure. It follows that effort must be 
concentrated on the prevention of PKDL, which develops 
after treatment of VL. Unfortunately, except for SSG, the 
incidence of PKDL following any other treatment regimen 
either as monotherapy or combination therapy has not yet 
been systematically studied. Studies on the incidence of 
PKDL following different treatment regimens should be 
undertaken so as to identify better treatments associated 
with the least incidence of PKDL and without compromis-
ing its efficacy and safety against VL. Prospective active 
surveillance of cured VL patients is needed and patients 
treated under different drugs are ideal resources for eventual 
prospective surveillance. A recent study in India showed that 
treatment of VL with AmBisome at a total dose 20 mg/kg 
was associated with 0.3% incidence of PKDL in the cohort.14 
This is far less than with SSG monotherapy, which was 19% 
within 5 years after treatment. However, as PKDL patients 
seldom self-report to medical care facilities, active surveil-
lance is needed to get the real estimate of PKDL incidence 
after treatment with a higher dose of AmBisome to make it 
comparable to the incidence of PKDL after other treatment 
regimens.
According to the available literature, one of the key points 
in the pathogenesis of PKDL is inadequate immune response 
to infection during and after the treatment of VL. Persistence 
of a mixed cellular immune response characterized by high 
levels of IL-10 and IFNγ after complete treatment of VL is 
associated with development of PKDL.52 Therefore, immuno-
prophylaxis during the treatment of VL so as to enhance Th1 
cellular immune responses along with a well-tuned immuno-
regulatory response to infection may prevent the development 
of PKDL after treatment of VL. This is supported by the 
findings of the study in Sudan in which PKDL treatment was 
substantially improved by adding alum/alum + BCG vaccine 
to the conventional treatment with SSG.31 LEISH F3 is the 
only US Food and Drug Administration (FDA)-approved 
vaccine in clinical trials for the prevention of VL. If it is 
found to be safe among the population where PKDL is com-
mon, then clinical trials with LEISH-F3 for the prevention 
of PKDL will be recommendable (personal communication 
with Dr Steve Reed, Director, Infectious Diseases Research 
Institute, Seattle, WA, USA).
In conclusion, there are several challenges for the man-
agement of PKDL. PKDL plays a crucial role as a reservoir Research and Reports in Tropical Medicine 2014:5 submit your manuscript | www.dovepress.com
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during interepidemic transmission of VL especially in 
the Indian subcontinent where VL is only anthroponotic. 
However, it remains the most neglected issue among 
neglected diseases. In recent years, the burden of VL has 
substantially declined, which makes it appropriate to focus 
the efforts of donors, policymakers, and researchers on find-
ing ways to effectively combat PKDL once and for all.
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